Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : INCY    crawled date : 2021 - 03 - 23    save search
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
INCY | $51.69 0.08% 45K twitter stocktwits trandingview |
Health Technology
 | | O: -0.15% H: 0.25% C: -2.08%
treatment therapy cancer growth approval
Gainers vs Losers
69% 31%

Top 10 Gainers
CZOO | $9.98 100.0% 330K twitter stocktwits trandingview |

AMST | $3.48 74.0% 21M twitter stocktwits trandingview |
Technology Services
BOF | $1.78 52.14% 15M twitter stocktwits trandingview |

CSSE 4 | $0.2184 43.4% 36M twitter stocktwits trandingview |
Consumer Services
MULN | News | $3.445 26.19% 980K twitter stocktwits trandingview |
Information
LICN | $0.6987 24.77% 4.4M twitter stocktwits trandingview |

HKIT | $1.6 20.3% 160K twitter stocktwits trandingview |
Technology Services
IMMP | $2.95 17.53% 260K twitter stocktwits trandingview |
Health Technology
MTC | $2.63 17.41% 3.3M twitter stocktwits trandingview |
Technology Services
ACB | $7.32 16.56% 780K twitter stocktwits trandingview |
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.